Paper36136306
Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L and 9 others. JAMA Otolaryngol Head Neck Surg, 2022. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer. Papers, record 36136306. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36136306
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| Head and Neck Neoplasms | Major topic |
| Male | |
| Humans | |
| Middle Aged | |
| Cetuximab | |
| Carboplatin | |
| Cisplatin | |
| Squamous Cell Carcinoma of Head and Neck | |
| Cohort Studies | |
| Chemoradiotherapy | |
| Antineoplastic Combined Chemotherapy Protocols |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 36480179 | Problems With Interpreting Treatment Effects in Observational Competing Risks Data. | https://conductscience.org/library/papers/36480179 | PubMed |
| Comment in | 36480187 | Problems With Interpreting Treatment Effects in Observational Competing Risks Data-Reply. | https://conductscience.org/library/papers/36480187 | PubMed |
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34098030 | Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study. | Int J Radiat Oncol Biol Phys | 2021 | https://conductscience.org/library/papers/34098030 | PubMed |
| 2 | 25936651 | Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. | Oral Oncol | 2015 | https://conductscience.org/library/papers/25936651 | PubMed |
| 3 | 21225900 | Multiple imputation using chained equations: Issues and guidance for practice. | Stat Med | 2011 | https://conductscience.org/library/papers/21225900 | PubMed |
| 4 | 25366680 | Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/25366680 | PubMed |
| 5 | 22261362 | Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22261362 | PubMed |
| 6 | 30449625 | Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. | Lancet | 2019 | https://conductscience.org/library/papers/30449625 | PubMed |
| 7 | 21969503 | Human papillomavirus and rising oropharyngeal cancer incidence in the United States. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21969503 | PubMed |
| 8 | 20530316 | Human papillomavirus and survival of patients with oropharyngeal cancer. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20530316 | PubMed |
| 9 | 25492084 | Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25492084 | PubMed |
| 10 | 19634161 | Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. | Cancer | 2009 | https://conductscience.org/library/papers/19634161 | PubMed |
| 11 | 26232905 | Cardiovascular Disease Risk Factors Among Male Veterans, U.S., 2009-2012. | Am J Prev Med | 2016 | https://conductscience.org/library/papers/26232905 | PubMed |
| 12 | 25132089 | Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). | Oral Oncol | 2014 | https://conductscience.org/library/papers/25132089 | PubMed |
| 13 | 16467544 | Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16467544 | PubMed |
| 14 | 31609479 | Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. | Int J Cancer | 2020 | https://conductscience.org/library/papers/31609479 | PubMed |
| 15 | 21947123 | Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study. | Strahlenther Onkol | 2011 | https://conductscience.org/library/papers/21947123 | PubMed |
| 16 | 26270931 | Characteristics of Human Papillomavirus-Associated Head and Neck Cancers in a Veteran Population. | JAMA Otolaryngol Head Neck Surg | 2015 | https://conductscience.org/library/papers/26270931 | PubMed |
| 17 | 25013689 | Veterans and risk of heart disease in the United States: a cohort with 20 years of follow up. | Int J Prev Med | 2014 | https://conductscience.org/library/papers/25013689 | PubMed |
| 18 | 22550060 | Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. | Oncologist | 2012 | https://conductscience.org/library/papers/22550060 | PubMed |
| 19 | 33052757 | ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33052757 | PubMed |
| 20 | 32073648 | A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. | Cancer | 2020 | https://conductscience.org/library/papers/32073648 | PubMed |
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42532979 | The Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin. | Cancer Med | 2026 | https://conductscience.org/library/papers/42532979 | PubMed |
| 42322527 | Cancer-associated fibroblasts as a target in head and neck squamous cell carcinoma: bridging mechanisms to therapy with drugs, adjuvants, and nanotechnology. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42322527 | PubMed |
| 41465310 | Platinum Meets Pyridine: Affinity Studies of Pyridinecarboxylic Acids and Nicotinamide for Platinum-Based Drugs. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465310 | PubMed |
| 41344314 | Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience. | J Natl Cancer Inst | 2026 | https://conductscience.org/library/papers/41344314 | PubMed |
| 41228343 | Retrospective Trial on Cetuximab Plus Radiotherapy in Elderly Patients with Head and Neck Squamous Cell Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228343 | PubMed |
| 41212257 | Otoprotective measures for cisplatin-based chemoradiotherapy-induced toxicity in patients with head and neck cancer: a systematic review and meta-analysis. | Support Care Cancer | 2025 | https://conductscience.org/library/papers/41212257 | PubMed |
| 40763210 | Tumor-infiltrating nociceptor neurons promote immunosuppression. | Sci Signal | 2025 | https://conductscience.org/library/papers/40763210 | PubMed |
| 40353748 | Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40353748 | PubMed |
| 40323514 | Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data. | Int J Clin Oncol | 2025 | https://conductscience.org/library/papers/40323514 | PubMed |
| 39641447 | Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis. | Immunotherapy | 2024 | https://conductscience.org/library/papers/39641447 | PubMed |
| 39551064 | Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. | Lancet Oncol | 2024 | https://conductscience.org/library/papers/39551064 | PubMed |
| 39093329 | Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review. | J Cancer Res Clin Oncol | 2024 | https://conductscience.org/library/papers/39093329 | PubMed |
| 38992100 | Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients. | Oncogenesis | 2024 | https://conductscience.org/library/papers/38992100 | PubMed |
| 38727853 | Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma. | Int J Clin Oncol | 2024 | https://conductscience.org/library/papers/38727853 | PubMed |
| 37843751 | Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma. | Int J Clin Oncol | 2024 | https://conductscience.org/library/papers/37843751 | PubMed |
| 37831345 | Study of anticancer effects of platinum levetiracetam and levetiracetam via cancer biomarkers genes expression on HepG2 cell line. | Mol Biol Rep | 2023 | https://conductscience.org/library/papers/37831345 | PubMed |
| 37664029 | Real-world study of patients with locally advanced HNSCC in the community oncology setting. | Front Oncol | 2023 | https://conductscience.org/library/papers/37664029 | PubMed |
| 37576899 | De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: evolving paradigms and future strategies. | Front Oncol | 2023 | https://conductscience.org/library/papers/37576899 | PubMed |
| 37444388 | Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN). | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37444388 | PubMed |
| 37439286 | Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. | Head Neck | 2023 | https://conductscience.org/library/papers/37439286 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36136306
GET https://conductscience.org/api/papers/v1/36136306/references?page=2